Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
Summary: Antigen selection and prioritization represent crucial determinants of vaccines’ efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoa...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223003656 |
| _version_ | 1811154334430265344 |
|---|---|
| author | Hajer Fritah Michele Graciotti Cheryl Lai-Lai Chiang Anne-Laure Huguenin- Bergenat Rémy Petremand Ritaparna Ahmed Philippe Guillaume Julien Schmidt Brian J. Stevenson David Gfeller Alexandre Harari Lana E. Kandalaft |
| author_facet | Hajer Fritah Michele Graciotti Cheryl Lai-Lai Chiang Anne-Laure Huguenin- Bergenat Rémy Petremand Ritaparna Ahmed Philippe Guillaume Julien Schmidt Brian J. Stevenson David Gfeller Alexandre Harari Lana E. Kandalaft |
| author_sort | Hajer Fritah |
| collection | DOAJ |
| description | Summary: Antigen selection and prioritization represent crucial determinants of vaccines’ efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effective in vitro peptide-MHC binding affinity and peptide immunogenicity significantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines. |
| first_indexed | 2024-04-10T04:15:08Z |
| format | Article |
| id | doaj.art-9001342654b947c8becf2723dc803e5f |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-10T04:15:08Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-9001342654b947c8becf2723dc803e5f2023-03-12T04:21:56ZengElsevieriScience2589-00422023-04-01264106288Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinityHajer Fritah0Michele Graciotti1Cheryl Lai-Lai Chiang2Anne-Laure Huguenin- Bergenat3Rémy Petremand4Ritaparna Ahmed5Philippe Guillaume6Julien Schmidt7Brian J. Stevenson8David Gfeller9Alexandre Harari10Lana E. Kandalaft11Ludwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne, SwitzerlandLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland; Corresponding authorLudwig Institute for Cancer Research, Lausanne Branch, and Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, 1011, Switzerland; Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland; Corresponding authorSummary: Antigen selection and prioritization represent crucial determinants of vaccines’ efficacy. Here, we compare two personalized dendritic cell-based vaccination strategies using whole-tumor lysate or neoantigens. Data in mouse and in cancer patients demonstrate that peptide vaccines using neoantigens predicted on the sole basis of in silico peptide-major histocompatibility complex (MHC) binding affinity underperform relative to whole-tumor-lysate vaccines. In contrast, effective in vitro peptide-MHC binding affinity and peptide immunogenicity significantly improve the prioritization of tumor-rejecting neoepitopes and result in more efficacious vaccines.http://www.sciencedirect.com/science/article/pii/S2589004223003656Molecular medicineImmunityCancer |
| spellingShingle | Hajer Fritah Michele Graciotti Cheryl Lai-Lai Chiang Anne-Laure Huguenin- Bergenat Rémy Petremand Ritaparna Ahmed Philippe Guillaume Julien Schmidt Brian J. Stevenson David Gfeller Alexandre Harari Lana E. Kandalaft Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity iScience Molecular medicine Immunity Cancer |
| title | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity |
| title_full | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity |
| title_fullStr | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity |
| title_full_unstemmed | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity |
| title_short | Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity |
| title_sort | cancer vaccines based on whole tumor lysate or neoepitopes with validated hla binding outperform those with predicted hla binding affinity |
| topic | Molecular medicine Immunity Cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223003656 |
| work_keys_str_mv | AT hajerfritah cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT michelegraciotti cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT cheryllailaichiang cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT annelaurehugueninbergenat cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT remypetremand cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT ritaparnaahmed cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT philippeguillaume cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT julienschmidt cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT brianjstevenson cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT davidgfeller cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT alexandreharari cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity AT lanaekandalaft cancervaccinesbasedonwholetumorlysateorneoepitopeswithvalidatedhlabindingoutperformthosewithpredictedhlabindingaffinity |